Posts tagged: relapse

© 2017 American Academy of Neurology. Neurology. November 28, 2017; 89 (22) Eric C. Klawiter, Riley Bove, Liene Elsone, Enrique Alvarez, Nadja Borisow, Melissa Cortez, Farrah Mateen, Maureen A. Mealy, Jaime Sorum, Kerry Mutch, Sean…

J Clin Neurosci. 2016 Apr;26:168-70. doi: 10.1016/j.jocn.2015.08.033. Epub 2015 Dec 15. Dai Y1, Lu T1, Wang Y1, Fang L1, Li R1, Kermode AG2, Qiu W3….

CNS Neurosci Ther. 2016 Aug;22(8):677-85. doi: 10.1111/cns.12559. Epub 2016 May 24. Fu Y1, Yan Y1, Qi Y1, Yang L1, Li T1, Zhang N1, Yu C1,…

Low Serum Vitamin D Levels and Recurrent Inflammatory Spinal Cord Disease Maureen A.

Neuromyelitis optica and pregnancy B. Bourre, MD, R. Marignier, MD, H

OBJECTIVE: To investigate the clinical relevance of memory Th17 cells in patients with neuromyelitis optica (NMO) or multiple sclerosis (MS). PATIENTS AND METHODS: The proportion of peripheral memory Th17 cells was determined by flow cytometry. Sera IL-17A and IL-23 levels were detected by ELISA kits

Background: Neuromyelitis optica (NMO) is an aggressive devastating autoimmune disorder affecting predominantly optic nerves and the spinal cord. We are able to assess the serum antibodies against aquaporin 4 (anti-AQP4 Ab, also known as NMO-IgG), which are highly sensitive and specific for NMO.

It is known that pregnancy influences the relapsing rate of multiple sclerosis (MS); however, interaction between pregnancy and relapse of neuromyelitis optica (NMO), a distinct disease from MS, remains unclear. A 34-year-old woman who 1 year previously had clinical history of Sj?gren syndrome complicated by myelitis with the presence of anti-AQP4 antibody in her serum, although there was no optic neuritis involvement, was neurologically normal at time of becoming pregnant.

Neuromyelitis optica (NMO) is a relapsing inflammatory disorder of the central nervous system that closely resembles multiple sclerosis.

We report cases of Japanese sisters with neuromyelitis optica (NMO).

Background: Neuromyelitis optica (NMO) is a severe demyelinating disease often leading to serious disability. Accumulating evidence now implicates humoral mechanisms in its pathogenesis.

BACKGROUND: Under the therapeutic point of view, neuromyelitis optica (NMO) poses major challenges. Patients with NMO manifest severe disability from recurrent demyelinating lesions and the therapies are only partially effective. We performed a retrospective analysis of the records of patients followed at our institution and provide suggestions for management of acute relapses and preventive therapy.